SCHEMBL10244151

SCHEMBL10244151

CCNCCN[C@@H](C)c1cccc(O)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 4/20 0.56
LMNA P02545 4/20 0.56
GALR3 O60755 1/20 0.56
OPRK1 P41145 2/20 0.48
ADRA1A P35348 3/20 0.44
ADRB1 P08588 2/20 0.44
HTR1A P08908 2/20 0.44
ADRA2A P08913 2/20 0.44
DRD1 P21728 2/20 0.44
DRD3 P35462 2/20 0.44
SLC6A3 Q01959 2/20 0.44
TSHR P16473 2/20 0.44
ADRB2 P07550 1/20 0.44
ADRB3 P13945 1/20 0.44
ADRA2B P18089 1/20 0.44
ADRA2C P18825 1/20 0.44
NFKB1 P19838 1/20 0.44
HTR7 P34969 1/20 0.44
ADRA1B P35368 1/20 0.44
RAB9A P51151 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10243943 1.00 HIF1A (0.56) HIF1ALMNAGALR3OPRK1ADRA1A
SCHEMBL10282520 0.84 HIF1A (0.54) HIF1ALMNAGALR3OPRK1ADRA1A
SCHEMBL10282560 0.84 HIF1A (0.54) HIF1ALMNAGALR3OPRK1ADRA1A
SCHEMBL335330 0.81 OPRK1 (0.50) HIF1ALMNAGALR3OPRK1ADRA1A
SCHEMBL334407 0.81 OPRK1 (0.50) HIF1ALMNAGALR3OPRK1ADRA1A
SCHEMBL12608566 0.80 CYP3A4 (0.61) LMNAADRA1AHTR1AADRA2ADRD1
SCHEMBL12157543 0.80 CYP3A4 (0.61) LMNAADRA1AHTR1AADRA2ADRD1
SCHEMBL29291394 0.78 OPRK1 (0.54) HIF1ALMNAGALR3OPRK1ADRA1A
SCHEMBL15131066 0.78 DRD3 (0.70) HIF1ALMNAOPRK1ADRA1AADRB1
SCHEMBL10243804 0.77 OPRK1 (0.44) HIF1ALMNAGALR3OPRK1ADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 HIF1A 2687/4885LMNA 1467/4885GALR3 2595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.